Abstracts tagged "gout"

Abstract Number: 2014 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Approximately 70% of adults with gout have CKD (Chronic Kidney Disease) ≥stage 3 (i.e estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2), significantly restricts treatment…
Abstract Number: 1993 • ACR Convergence 2025
Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
Tingting Zhang¹, Christian W. Mende², Ashraf El-Meanawy³, Michael Pillinger⁴, Kaiding Zhu⁵, Bradley Marder⁶ and Brian Lamoreaux⁷, ¹Amgen, Inc., Thousand Oaks, ²University of California San Diego, San Diego, CA, ³Medical College of Wisconsin, Milwaukee, WI, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Amgen, Inc., San Francisco, CA, ⁶AMGEN, Inc, Denver, CO, ⁷Amgen, Inc., Deerfield, IL
Background/Purpose: Gout may increase the risk of cardiovascular events (CVEs) and bone fractures through urate deposition and chronic inflammation1,2. However, the additional effects of uncontrolled…
Abstract Number: 1139 • ACR Convergence 2025
Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
Sabahat Usmani¹, Gunjan Rana², Shivum Patel¹, Patrick Kennedy¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, ²Saint Vincent Hospital, Worcester, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Synovial fluid analysis is an essential diagnostic tool for evaluating crystalline and infectious arthritis. Traditionally, a leukocyte count threshold of >50,000 cells/µL has been…
Abstract Number: 0228 • ACR Convergence 2025
Bridging the Gap: Leveraging eConsultation to Improve Access to Quality Gout Care
Laura Nichols¹ and Steven Taylor², ¹University of Colorado, Aurora, CO, ²University of Colorado, Denver, CO
Background/Purpose: In the context of the rheumatology workforce shortage, eConsultation holds significant potential to address some challenges through supporting primary care providers in managing rheumatologic…
Abstract Number: 2013 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Acute gouty arthritis(GA) is a common and debilitating condition, especially for patients unsuitable for standard therapy. Firsekibart, previously called Genakumab, is a first-in-class fully…
Abstract Number: 1994 • ACR Convergence 2025
Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
Orrin Troum¹, John Botson², Afroz S. Mohammad³, Xiaoqing Yang⁴, Nathan Roe⁵, Supra Verma⁶ and Brian Lamoreaux⁷, ¹Providence Health Care/Doctor's of St John's (MDSJ) Santa Monica, CA, Santa Monica, CA, ²Orthopedic Physicians Alaska, Anchorage, AK, ³Amgen Inc, Deerfield, ⁴Amgen, Seattle, WA, ⁵Horizon Therapeutics, Boise, ID, ⁶Horizon Therapeutics, Newport Beach, CA, ⁷Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase is approved for uncontrolled gout as 8-mg infusions admixed in 250 cc of normal saline over 120 minutes or more administered every 2…
Abstract Number: 1133 • ACR Convergence 2025
A Proteomic Analysis Of Subclinical Synovial Inflammation Associated With Monosodium Urate Crystal Deposition
Mariano Andrés¹, María-Luisa Peral-Garrido², Samanta Ortuño³, Rocío Caño³, Silvia Gómez-Sabater³, Alejandra Bermúdez⁴, Teresa Lozano⁵, Miguel Perdiguero⁵, elena Caro-Martínez⁶, Ruth Sánchez-Ortiga⁵, Carolina Ruiz-García⁷, Eliseo Pascual⁸ and Rubén Francés⁸, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Vinalopó University Hospital, Novelda, Spain, ³Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ⁴Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ⁵Dr Balmis General University Hospital, Alicante, Spain, ⁶HACLE San Vicente Hospital, San Vicente del Raspeig, Spain, ⁷Campoamor Health Center, Alicante, Spain, ⁸Miguel Hernandez University of Elche, Alicante, Spain
Background/Purpose: Persistent subclinical inflammation from monosodium urate (MSU) crystals is present in gout and asymptomatic hyperuricemia (AH). The underlying mechanism is poorly understood. This study…
Abstract Number: 0171 • ACR Convergence 2025
The Association Between Short-Term Trajectory Of Atmospheric Particulate Matter 10 (PM10) Concentration And Hyperuricemia
Sunggun Lee¹, Minyoung Her¹, Seong-HO Kim¹, Yong-Gil Kim² and Ji Seon Oh², ¹Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea
Background/Purpose: The association between high atmospheric particulate matter concentration and gout flare has been reported1, but the causality and mechanism of this association remain unknown.…
Abstract Number: 2011 • ACR Convergence 2025
A Phase 1 placebo controlled, single (SAD) and multiple dose escalation (MAD) safety and pharmacokinetic (PK) study of a novel colchicine analogue ABP-745 in healthy volunteers (HV)
ullrich schwertschlag¹, Roy Wu², yan yang³ and William Shi⁴, ¹Atom Therapeutics, PALO ALTO, CA, ²Atom Bioscience, San Francisco, CA, ³Atom Therapeutics, Suzhou, China (People's Republic), ⁴Atom Therapeutics, Newark, CA
Background/Purpose: ABP-745 is a novel colchicine analogue in development as an anti-inflammatory agent for the treatment of acute gout and other chronic inflammatory conditions. In…
Abstract Number: 1992 • ACR Convergence 2025
Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
Vinicius Domingues¹, Alexis Woods², Xiaoqing Yang³, Brian Lamoreaux⁴ and Michael Weinblatt⁵, ¹Rheumatology, Allergy, Asthma & Arthritis Center, Daytona beach, FL, ²Amgen, Detroit, MI, ³Amgen, Seattle, WA, ⁴Amgen, Inc., Deerfield, IL, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Methotrexate (MTX) coadministered with pegloticase attenuates anti-drug antibody formation, leading to higher response rates and markedly reduced infusion reaction risk compared with pegloticase +…
Abstract Number: 1132 • ACR Convergence 2025
DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk
Linrui Zhong, Tianyi Lei, Quanbo Zhang and Yufeng Qing, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic)
Background/Purpose: Pyroptosis is closely linked to acute flare-ups and spontaneous remission of gout. However, the specific mechanisms by which pyroptosis regulates gout inflammation remain unclear.…
Abstract Number: 0082 • ACR Convergence 2025
IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model
Hongling Tian, Lidan Liang, Chenjuan Zhu, Bin Li, Lei Cao, Meng Ni, Fan Chen, Zhimin Zhang, Min Wu, Tong Liu, Jinyang Li, Yao Xiong, Li Li, Shuaixiang Zhou, Enhong Zhong and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Interleukin 1 receptor accessory protein (IL1RAP) serves as a co-receptor that forms receptor complexes with IL1R1, ST2, and IL36R and mediates signaling pathways triggered…
Abstract Number: 2010 • ACR Convergence 2025
Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli
Tony Merriman¹, Christopher Hall², Annie Chien², Richard Reynolds³, Jeffrey Edberg³, Pariyaphon Lertprachakwong³, Hannah Darroch⁴, Megan Leask⁴, Mumin Ozturk⁵, Brenda Kischkel⁵, Nicholas Sumpter⁵, Leo Joosten⁵ and Nils Asmann⁵, ¹University of Alabama at Birmingham, Homewood, AL, ²University of Aucklabd, Auckland, New Zealand, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Otago, Dunedin, New Zealand, ⁵Radboud University Medical College, Nijmegen, Netherlands
Background/Purpose: CSF1 and CSF1R encode a secreted and membrane-bound cytokine and its receptor controlling differentiation of monocytes into macrophages and inflammatory activity of macrophages. There…
Abstract Number: 1990 • ACR Convergence 2025
Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Alex Tinianow¹, Saiajay Chigurupati¹, Ethan Carey¹, Jiaqi Wang², Sharan Rai³, Gregory Challener⁴, Hyon K. Choi⁵, Philip Riches⁶, Natalie McCormick¹ and Chio Yokose⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, BOston, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴MGH, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶NHS Lothian, Edinburgh, UK, Edinburgh, United Kingdom, ⁷Massachusetts General Hospital, Waltham, MA
Background/Purpose: Rheumatology guidelines endorse a treat-to-target (TTT) approach targeting serum urate (SU) < 6 mg/dL among patients with gout who qualify for urate-lowering therapy (ULT).…
Abstract Number: 1131 • ACR Convergence 2025
Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance
Yuqi wang¹, Lingjiang Zhu¹, Jinshuo Han², Junbin Qian³, Martin Herrmann⁴, Jing Xue¹ and Lei Liu¹, ¹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ²Zhejiang University, School of Medicine, Hangzhou, China (People's Republic), ³Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ⁴University Hospital Erlangen, Erlangen, Germany
Background/Purpose: While aggregated neutrophil extracellular traps (aggNETs) constitute the primary structural component of tophi, the susceptible population for tophaceous gout remains poorly characterized. We investigated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].